Application of Box-Behnken design for optimization of phenolics extraction from Leontodon hispidulus in relation to its antioxidant, anti-inflammatory and cytotoxic activities.

To the best of our knowledge, there have been no phytochemical studies concerning the wild plant Leontodon hispidulus Boiss. (Asteraceae). Optimization of the green extraction process of the plant aerial parts, identification of main phenolic compounds, evaluation of antioxidant, anti-inflammatory and anticancer activities of the optimized extract have been carried out. HPLC-analysis was performed using 95% ethanolic extract. 3-Level Box-Behnken Design was applied for optimization of extraction yield and total phenolic content using 3-factors (ethanol/water ratio, material/solvent ratio and extraction time). Antioxidant, anticancer and anti-inflammatory activities were evaluated by ABTS-assay, prostate and cervical carcinoma human cell lines and carrageenan-induced rat paw edema model, respectively. HPLC-analysis showed the presence of quercetin, rutin, kaempferol, chlorogenic and ρ-coumaric acids. Increasing both ethanol/water ratio and material/solvent ratio decreased the yield, while, it increased by prolongation of the extraction time. High material/solvent ratio increased the phenolic content. The optimized extract showed high total phenolic content (104.18 µg/mg) using 201 ml of 74.5% ethanol/water at 72 h and good biological activities. Antioxidant activity was found to be 41.89 mg Trolox-equivalent/gm, with 80% free radicals inhibition. For anti-inflammatory activity, 100 mg/kg of the extract inhibited the edema in rats by 83.5% after 4 h of carrageenan injection as compared to 81.7% inhibition by indomethacin. Prostate carcinoma cell line was more sensitive to the anticancer activity of the extract than cervical carcinoma cell line (IC50 = 16.5 and 23 µg/ml, respectively). The developed extraction procedure proved to be efficient in enriching the extract with phenolic compounds with promising anticancer, anti-inflammatory and antioxidant activities.

In vivo antidiabetic potential of standardized Gymnocarpos decandrus Forssk. Extract.

BACKGROUND: Gymnocarpos decandrus (Caryophyllaceae) is a well-known wild plant used as a food for grazing animals. Recently it showed potent antidiabetic potential beside its established anti-inflammatory, analgesic and diuretic activities. G. decandrus antidiabetic potential was reported through in-vitro models and resulted in promising α-amylase, α-glucosidase and antiviral Coxsackie B4 inhibitory activities; however no in-vivo studies were conducted. PURPOSE: This study aims to examine Gymnocarpos decandrus ethanol extract (GDEE) safety and to evaluate its in vivo antidiabetic potential. METHOD: Adult albino rats were injected intraperitoneally with alloxan to induce diabetes mellitus and the glucose level was measured after two and four weeks against metformin as a standard drug. Additionally, GDEE characterization and standardization were carried out. RESULTS: GDEE LD50 was up to 5.8 mg/kg and exhibited significant antidiabetic activity 77.17% comparable to the standard drug metformin. Its total phenolics, and flavonoids amounted 127.2 ± 0.23 and 85.5 ± 0.21 mg/g respectively. Vitexin was used as a marker compound for GDEE (140.70 mg/100 gm). CONCLUSION: This study represents the sole in vivo scientific validation of G. decandrus recently documented in vitro antidiabetic potential.

Validation of Antidiabetic Potential of Gymnocarpos decandrus Forssk.

Gymnocarpos decandrus Forssk. is a well-known grazing wild plant. This study targets scientific validation of its claimed antidiabetic activity and exploring its bioactive metabolites. Chromatographic purification of G. decandrus ethanol extract (GDEE) allowed isolation of vitexin (C1), protocatechuic acid (C2) and quercetin (C3). HPLC-PDA-MS/MS enabled identification of nineteen metabolites; 13 flavonoids, 5 saponins, and 1 phenolic acid in G. decandrus and four in the genus Gymnocarpos for the first time. The antidiabetic potential was evaluated via testing the Coxsackie B4 virus and α-glucosidase inhibitory potentials. C3 exhibited its potent antiviral activity through blocking of the virus attachment (96.28%, SI 4.41) and virus inactivation before adsorption (91.47%, SI 4.78). GDEE and C1-C3 showed dose dependent α-glucosidase inhibitory activity with IC50 of 733.9, 293.3, 118.1 and 69.1 µg/mL, respectively. Our study represents the sole complete map for G. decandrus secondary metabolites and presents it as promising drug for diabetes management.